Opportunity mapping for hemojuvelin antibody

Challenge: A US-based biotech company developing a novel biologic which impacts iron metabolism, wanted help deciding which disease and patient groups would make the best lead indication for...
Learn More

Indication prioritization for oligonucleotide-based therapeutics targeting age-related disorders

Challenge: A university spinout was developing oligonucleotide therapeutics to address age-related disorders. The company wanted to understand the most attractive lead indications in which to focus...
Learn More

Comparing clinical response rates for Tumor Infiltrating Lymphocytes against other therapeutic modalities

Challenge Alacrita supported the European arm of a major company creation investor as part of an ongoing workstream to evaluate the benefits of refocusing its investments into the tumour infiltrating...
Learn More

Development plan validation for novel small molecule for cancer

Challenge: For a university with an early stage novel inhibitor of the JAK2/STAT5 pathway intended to treat hematologic malignancies, Alacrita was asked to validate a development plan to support...
Learn More

Valuation of a novel oncology program to support fundraising and M&A opportunities

Challenge An early stage virtual company developing a siRNA knock-down technology to increase chemo-sensitivity of tumor cells had developed a specific formulation of its siRNA therapeutic using a...
Learn More

Supporting a PE Fund with Radiopharmaceutical Opportunity Mapping & Market Landscaping

Challenge A private equity fund which had successfully invested in the advanced biologics CDMO space was considering entering the radiopharmaceuticals CDMO space through investment in an established...
Learn More

Characterizing the European commercial opportunity for a microbiome company

Challenge: A clinical stage microbiome company was developing a microbiome therapeutic for the treatment of recurrent C. Difficle infection (rCDI). The company was progressing through clinical...
Learn More

Glycan biomarker discovery market research in North America

Challenge A glycan biomarker research company with a proprietary platform offering biomarker discovery and characterization, diagnostic development and commercialization asked Alacrita to help them...
Learn More

Business plan and fundraising for cell therapy company

Challenge An early stage, European cell therapy company focused on developing novel off-the-shelf NK cell therapy solutions for the treatment of a variety of cancers had developed a platform...
Learn More

Investor pitch deck for biotech developing non-opioid analgesic

Challenge A start-up US biotech developing a non-opioid analgesic drug and delivery device was preparing to raise its first round of external funding. They engaged Alacrita to help frame the target...
Learn More

Business plan for opioid overdose detection device

Challenge Our client was a start-up looking to raise external venture capital funding for development of a biosensor for early detection of opioid overdose. The company had drafted a business plan...
Learn More

Commercial viability of a bacterial biomarker test

Challenge A leading UK university and an executive agency of the DoH were collaboratively developing a rapid (30 min) bacterial ID and antimicrobial resistance test platform. The technology...
Learn More
1 2 3 4 5